| antag | antagonist |
|---|---|
| CA | anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can... |
| FAA | folic acid antagonist; formaldehyde, acetic acid, alcohol |
| FABP | fatty acid-binding protein; folate-binding protein |
| FBP | femoral blood pressure; fibrin breakdown product; folate-binding protein; fructose-1, 6-biphosphatas... |
| FBP | Folate binding protein |
|---|---|
| FR | Folate receptor |
| FRalpha | Folate receptor alpha |
| RCF | Red cell folate |
| RFC | Reduced folate carrier |
| folate antagonist | <pharmacology> One of a group of substances which blocks the formation of nucleotides that require the presence of folate (one of the B vitamins) before they can be made. The substance does this by blocking key steps in the reaction sequence. These substances are often used to treat cancer because fast-growing cancerous cells usually need to use the blocked reactions more than normal cells. (09 Oct 1997) |
|---|
| sodium folate | The sodium salt of folic acid; action and uses are the same as those of folic acid, but it is preferred for parenteral administration. Synonym: sodium pteroylglutamate. (05 Mar 2000) |
|---|---|
| folate | <biochemistry> Molecule that acts as a carrier of one carbon units in intermediary metabolism. It contains residues of p aminobenzoate, glutamate and a substituted pteridine. The latter cannot be synthesised by mammals, which must obtain tetrahydrofolate as a vitamin or from intestinal microorganisms. One carbon units are carried at three different levels of oxidation, as methyl, methylene or formimino groups. Important biosyntheses dependent on tetrahydrofolate include those of methionine, thymine and purines. Analogues of dihydrofolate, such as aminopterin and methotrexate block the action of tetrahydrofolate by inhibiting its regeneration from dihydrofolate. (18 Nov 1997) |
| aldosterone antagonist | An agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents, e.g., spironolactone, are useful in treating the hypertension of primary hyperaldosteronism, or the sodium retention of secondary hyperaldosteronism. (05 Mar 2000) |
| antagonist | <pharmacology> A substance that tends to nullify the action of another, as a drug that binds to a cell receptor without eliciting a biological response. Origin: Gr. Antagonistes = an opponent (18 Nov 1997) |
| associated antagonist | One of two muscles or groups of muscles which pull in nearly opposite directions, but which, when acting together, move the part in a path between their diverging lines of action. (05 Mar 2000) |
| beta-adrenoreceptor antagonist | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| calcium antagonist | calcium channel-blocking agent |
| calcium channel antagonist | <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools. Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms. Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent. (12 May 2002) |
| mixed opioid agonist-antagonist | <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type. (13 Nov 1997) |
| competitive antagonist | An antimetabolite. (05 Mar 2000) |
| muscarinic antagonist | Drugs which bind with muscarinic cholinergic receptors but do not activate them, thus preventing access to acetylcholine; examples include atropine, scopolamine, propantheline, and pirenzepine. (05 Mar 2000) |
| H2 antagonist | <pharmacology> A class of anti-ulcer medication which work through the inhibition of basal and nocturnal gastric acid secretion by competitive inhibition of the action of histamine at histamine H2 receptor sites on the parietal cells. Drugs of this type block gastric acid secretion and are therefore clinically useful in treating duodenal ulcers. Examples include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac). (27 Sep 1997) |
| insulin antagonist | Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin. (09 Oct 1997) |
| oestrogen antagonist | <pharmacology> A drug or compound which inhibit or antagonise the action or biosynthesis of oestrogen. Tamoxifen also has agonist or stimulatory actions as well as blocking effects. There are also selective oestrogen-receptor modulators (SERMs). For example, raloxifene (trade name Evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus. (12 May 2002) |
| enzyme antagonist | An antimetabolite or inhibitor of enzyme action. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|